Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03883412 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)

Study acronym: ZQL007
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Jun 2025 to Jun 2027
    • Study completion date: Dec 2025 to Dec 2027
    v5
  2. Primary completion date: Jun 2023 to Jun 2025
    • Study completion date: Dec 2023 to Dec 2025
    v4
  3. Primary completion date: Mar 2022 to Jun 2023
    • Study completion date: Mar 2022 to Dec 2023
    v3
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Virginia
167 trials monitored
See 8 trials at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
Type 2 Diabetes
2,231 trials monitored
See 111 trials at risk
The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and muscle capillary blood volume, improves vascular function in the larger conduit vessels, and enhances insulin's metabolic action in humans with Type 2 diabetes. Subjects will be randomized to one of the three groups: exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 16 weeks of intervention.
Trial Details
NCT Number NCT03883412
Lead Sponsor University of Virginia
Collaborators: American Diabetes Association, National Institutes of Health (NIH)
Conditions
(from sponsor)		 Type2 Diabetes
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov